# Exploring Anxiety, Depression, and Cannabis Use in the Endocannabinoid System > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/endocannabinoid-system-anxiety-cannabis-research/ > **Published:** 2026-04-22T23:41:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:55:26-04:00 > **Clinical Summary:** Explore endocannabinoid system anxiety cannabis research revealing links between adolescent mental health and cannabis use for informed prevention strategies. --- #### Clinical Takeaway Adolescents with depression and anxiety symptoms show increased [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) over 18 months, suggesting self-medication behavior in vulnerable populations. This longitudinal evidence indicates that mental health screening and early intervention may be important prevention strategies in adolescent populations. ### #15 Anxiety, depression and risk of cannabis use: Examining the internalising pathway to use among Chilean adolescents. **Citation:** Stapinski Lexine A et al. *Anxiety, depression and risk of cannabis use: Examining the internalising pathway to use among Chilean adolescents.* Drug and alcohol dependence. 2016. PMID: 27427415. **Study type:** Journal Article, Randomized Controlled Trial  |  **Topic area:** Pediatrics  |  **CED Score:** 11 Design: 5 Journal: 0 N: 4 Recency: 0 Pop: 3 Human: 1 Risk: -2 **Quality Gate Alerts:** - Preclinical only **Abstract:** BACKGROUND: Adolescents who experience internalising symptoms may be susceptible to the use of alcohol and other substances in an attempt to alleviate or cope with these symptoms. We examined the hypothesised internalising pathway from symptoms of depression, generalised anxiety, social anxiety and panic, to incidence and frequency of cannabis use 18 months later. METHOD: Longitudinal cohort study of participants (n=2508; 45% female; mean age 14.5 years) recruited from the 9th grade at 22 low-income secondary schools in Santiago, Chile. Baseline internalising symptoms were assessed using the Beck Depression Inventory and the Revised Child Anxiety and Depression Scale. Frequency of cannabis was assessed at baseline, 6 month and 18 month follow-up. RESULTS: High rates of use were observed in this sample, with 40.3% reporting cannabis use at least once over the study period. Adjusted for baseline cannabis use, symptoms of depression, panic and generalised anxiety were associated with greater cannabis use frequency 18 months later. When all predictors were considered simultaneously, only generalised anxiety symptoms showed an independent association with subsequent cannabis use frequency (OR: 1.23, 95% CI: 1.08-1.41). Generalised anxiety symptoms were also associated with a 25% increased risk of transitioning from non-user to use of cannabis during the study (OR: 1.25, 95% CI: 1.09-1.44). CONCLUSIONS: Internalising symptoms, and in particular symptoms of generalised anxiety, increase risk of cannabis use during adolescence. Targeted interventions that promote adaptive [anxiety management](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) among high-risk adolescents may represent a promising strategy to prevent uptake of cannabis use during adolescence.  |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/27427415/)[DOI ↗](https://doi.org/10.1016/j.drugalcdep.2016.06.032) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System & Adolescent Cannabis Use Risk](https://cedclinic.com/internalising-symptoms-cannabis-use-risk-adolescents/) Explore the risks associated with [adolescent cannabis use](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) and the role of the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) in mental health. [Read More](https://cedclinic.com/internalising-symptoms-cannabis-use-risk-adolescents/) [Endocannabinoid System Research: Cannabis Use in Teen Anxiety](https://cedclinic.com/anxiety-depression-cannabis-use-adolescents/) Delve into research examining cannabis use and anxiety in teens through the lens of the endocannabinoid system. [Explore Study](https://cedclinic.com/anxiety-depression-cannabis-use-adolescents/) [Cannabis Use in Adolescents: Understanding Endocannabinoid System’s Role in Anxiety & Depression](https://cedclinic.com/internalizing-pathway-cannabis-use-adolescents-anxiety/) Understand how the endocannabinoid system influences [adolescent cannabis](https://cedclinic.com/cannabis-use-disorder-psychiatric-risk/) use related to anxiety and depression. [Learn More](https://cedclinic.com/internalizing-pathway-cannabis-use-adolescents-anxiety/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Exploring%20Anxiety%2C%20Depression%2C%20and%20Cannabis%20Use%20in%20the%20Endocannabinoid%20System&url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-anxiety-cannabis-research%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-anxiety-cannabis-research%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Exploring%20Anxiety%2C%20Depression%2C%20and%20Cannabis%20Use%20in%20the%20Endocannabinoid%20System%20https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-anxiety-cannabis-research%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).